Prostate News and Research

RSS

Bisphenol A (BPA) has been linked to damage in developing brain tissue

The chemical bisphenol A (BPA), widely used in products such as food cans, milk container linings, water pipes and even dental sealants, has now been found to disrupt important effects of estrogen in the developing brain.

2 Dec 2005

Spear Therapeutics raise $8.5 Million to fund cancer drug development

Cancer Research Technology (CRT), Bloomsbury Bioseed Fund (BBSF), De Montfort University (DMU) and the Gray Cancer Institute announce today that U.S. venture capital firm Advent International has invested $8.5 million in Spear Therapeutics Ltd.

28 Nov 2005

Endorectal-body phased-array coil improves prostate cancer detection

The image quality for detecting prostate cancer is significantly better for MRI at 1.5 T using an endorectal-body phased-array coil as compared with the 3.0 T imaging using the torso phased-array coil, a recent study found.

28 Nov 2005

Two novel drugs kill breast cancer tumor cells

Two new drugs, when combined, killed up to 75 percent of breast cancer tumor cells in mice and suppressed the regrowth of tumors, according to researchers at the Virginia Commonwealth University Massey Cancer Center.

26 Nov 2005

Viagra effectively treats urinary tract symptoms associated with prostate enlargement

Viagra (sildenafil citrate), known for improving erectile dysfunction (ED), also effectively treats the prostate and lower urinary tract symptoms (LUTS) associated with prostate enlargement that often occur with ED, a Northwestern University study has found.

21 Nov 2005

Speed of PSA increase matters more than PSA level

In the largest study of its kind to date, Mayo Clinic researchers report that prostate specific antigen (PSA) kinetics, both velocity and doubling time, can be used to predict disease progression and likelihood of death after radical prostatectomy surgery, suggesting that this could be used to guide treatment decisions.

14 Nov 2005

Zyflamend shows promise in the early treatment of prostate cancer

Data from the Columbia University Department of Urology demonstrates that Zyflamend, a unique herbal extract preparation, suppresses the growth of prostate cancer cells and induces prostate cancer cells to self-destruct via a process called "apoptosis."

13 Nov 2005

Issues faced by cancer patients - assessement - impact - implications

New study findings showcased at the 13th European Cancer Conference (ECCO) have shed further light on the manifold factors which must be considered when managing patients with cancer. Studies from around Europe looked at a number of the issues faced by cancer patients and assessed their impact and associated implications.

3 Nov 2005

New therapies for prostate cancer

A Dutch study suggested treating prostate cancer patients with higher doses of radiotherapy significantly improved patient outcome and treatment over a five-year period.

3 Nov 2005

New targeted cancer drug delivery system

Prostate, breast and other cancer patients may be offered a new, stauncher targeted drug delivery system to treat their diseases in the next decade.

3 Nov 2005

DN-101 may protect against major side effects of chemotherapy

Men with advanced prostate cancer who take an experimental, high-dose vitamin D pill with chemotherapy live about eight months longer than those receiving chemotherapy and placebo, according to a new study.

3 Nov 2005

Calcitriol - promising chemopreventive agent that may prevent prostate cancer

The active metabolite of vitamin D, calcitriol, and other vitamin D analogs are promising chemopreventive agents that may prevent prostate cancer, according to a study presented today at the American Association for Cancer Research's 4th annual Frontiers in Cancer Prevention Research meeting in Baltimore.

3 Nov 2005

Targeted drug delivery now possible using nanoparticle-apatamer conjugates

Ground-breaking results from researchers at Harvard Medical School and Massachusetts Institute of Technology (MIT), USA, disclosed at the 13th European Cancer Conference (ECCO) have shown for the first time that targeted drug delivery is possible using nanoparticle-apatamer conjugates.

3 Nov 2005

Study examines cancer risks after cancer diagnosis in family

After a person is diagnosed with cancer, increased surveillance among their family members may result in the earlier detection of asymptomatic familial cancers.

3 Nov 2005

Combination of radiotherapy and a drug named S247 as a cure for cancer

Does a combination of radiation therapy and the inhibition of integrins (key molecules in angiogenesis) improve the chance of cure in cancer?

3 Nov 2005

Targeted drug delivery achieved with nanoparticle-aptamer bioconjugates

Ground-breaking results from researchers at Harvard Medical School and Massachusetts Institute of Technology (MIT), USA, disclosed at the 13th European Cancer Conference (ECCO) in Paris have shown for the first time that targeted drug delivery is possible using nanoparticle-apatamer conjugates.

1 Nov 2005

Role of alpha tocopherol associated protein in prostate cancer

Researchers have identified a protein that disrupts an important signaling pathway in prostate cancer cells and suppresses growth of the cancer.

1 Nov 2005

Functional diffusion map to help predict brain tumor outcomes

A special type of MRI scan that measures the movement of water molecules through the brain can help doctors determine halfway through treatment whether it will successfully shrink the tumor or a patient's cancer will continue to grow, a new study shows.

1 Nov 2005

Benefit of combining radiation and hormone therapy in the treatment of prostate cancer

Doctors in Canada have discovered that treating high-risk prostate cancer patients with radiation therapy and adding hormone therapy for more than one year allows patients to live longer, have better control of their prostate specific antigen levels and lowers the rate of death specifically from prostate cancer

1 Nov 2005

Discovery of signaling mechanism may help prevent metastatic melanoma

Researchers at Northwestern University have discovered a key signaling mechanism that may promote the ability of highly aggressive malignant melanoma cells to metastasize, or spread from a primary tumor to distant sites within the body.

1 Nov 2005